trial

Avatar Therapy in Comparison to Cognitive Behavioral Therapy for Treatment-resistant Schizophrenia

NCTId NCT03585127
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 74 (actual)
Sponsored by Ciusss de L'Est de l'Île de Montréal
Primary completion 2020-03-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
74 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2017-03-01
Primary completion
2020-03-31
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Cognitive Behavioral TherapyAvatar therapy

Sponsors

Ciusss de L'Est de l'Île de MontréalLead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Collaborator

Investigators

1
Alexandre Dumais, MD, Ph.DPrincipal Investigator

Sites

1 total
Montreal, Canada

Facts & assertions

4 sourced
Enrollment
74
Phase
NA
Primary Completion Date
2020-03-31
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Behavioral Therapy
drug
Avatar therapy
drug
lead_sponsor
Ciusss de L'Est de l'Île de Montréal
company
collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Hallucinations
indication
Treatment-resistant Schizophrenia
indication
Auditory Hallucination, Verbal
indication
investigator
Alexandre Dumais, MD, Ph.D
person